After a Clinical Hold, Rocket Maps Remaining Steps for RP-A501 in Danon Disease

Rocket Pharmaceuticals has outlined how it intends to complete the pivotal phase 2 trial of RP-A501, an investigational gene therapy for Danon disease, following an Oct. 6 investor webinar.¹

The company tied a recalibrated dose and a 12-patient efficacy population to a timeline that runs through topline results in mid-2028, leaving the program dependent on a small study.¹

“FDA’s confirmation of the pivotal efficacy framework marks an important milestone for RP-A501 and the Danon disease community,” said Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharmaceuticals, when the company announced agency alignment in September.²

What is the pivotal trial designed to show?

The study will treat 12 male patients with commercial-grade RP-A501 at the recalibrated dose, and the first three patients dosed under the modified protocol count toward that total.¹ Success requires at least seven patients to meet two criteria at 12 months: myocardial expression of lysosome-associated membrane protein 2 (LAMP2) of at least Grade 1, and a reduction in left ventricular mass index of at least 10% from baseline.¹

Rocket says these co-primary endpoints are intended to support a potential accelerated approval pathway, although its own risk disclosures note that FDA has yet to determine whether the evidence would suffice.¹

The September disclosure said the dose of 3.8 × 10¹³ genome copies per kilogram was chosen after analytical characterization of the commercial-grade product, including its full-particle content, and was supported by nonclinical bridging data from a Danon disease mouse model.²

That link between capsid composition and dose is a manufacturing question as much as a clinical one, and Rocket lists product comparability among its uncertainties.¹

What did earlier studies show, and what changed?

In the phase 1 study, seven male patients received a single infusion of RP-A501 alongside a transient immunomodulatory regimen.³ Among six patients with normal left ventricular ejection fraction at baseline, investigators observed cardiac LAMP2 expression and a reduction in or stabilization of left ventricular mass index over 24 to 54 months.³

Safety events included one case of grade 4 complement-mediated thrombotic microangiopathy and three cases of grade 3 glucocorticoid-related skeletal myopathy exacerbation, and one patient with systolic dysfunction at baseline underwent transplantation five months after infusion.³

Original-dose phase 2 results were more mixed. Three of four patients with longitudinal efficacy assessments reached the 10% reduction threshold, while safety findings, including thrombotic microangiopathy and a fatal serious adverse reaction, informed the current dose, a revised immunomodulation regimen and enhanced monitoring.¹

FDA lifted a clinical hold on the trial in August 2025, in under three months, and authorized resumption at the recalibrated dose in three patients treated at least four weeks apart.⁴ As BioPharm International reported in August, those first three patients showed no thrombotic microangiopathy or capillary leak syndrome. Rocket now says that held through the initial observation period, though follow-up is ongoing and the observations are preliminary.¹

Why does Danon disease remain a high unmet need?

Danon disease is a rare, X-linked disorder caused by mutation of the gene encoding LAMP2, leading to accumulation of autophagosomes and glycogen, particularly in cardiac muscle.¹ The result is heart failure and, for male patients, frequent death in adolescence or early adulthood.¹

Cardiac transplantation is the only definitive treatment, carries substantial complications and is not considered curative.¹ Rocket’s genetic and clinical analyses model a U.S. population of about 10,000 to 11,000 people, including 4,000 males, with an initial focus on males with symptomatic hypertrophic cardiomyopathy.¹ Those figures are modeled estimates.

What are the limitations and next steps?

The efficacy population is small, the trial is single-arm, and the company acknowledges that studies without randomized controls, differing doses, products and follow-up periods limit what earlier results can predict.¹ The safety observations at the recalibrated dose come from three patients with short follow-up.

A threshold of seven responders among 12 patients also means the outcome will rest on very small numbers. Open questions include whether FDA will accept the co-primary endpoints as sufficient for accelerated approval and whether product-bridging data hold up as additional patients are dosed.

Rocket expects to complete pivotal dosing by mid-2027, with topline results anticipated in mid-2028.¹

Sources

1. Rocket Pharmaceuticals highlights FDA-aligned pivotal phase 2 trial and updated clinical findings for RP-A501 following Danon disease investor webinar. News release. Business Wire. October 7, 2026. Accessed October 8, 2026. https://www.businesswire.com/news/home/20261007068126/en/Rocket-Pharmaceuticals-Highlights-FDA-Aligned-Pivotal-Phase-2-Trial-and-Updated-Clinical-Findings-for-RP-A501-Following-Danon-Disease-Investor-Webinar
2. Rocket Pharmaceuticals announces FDA alignment on path to complete pivotal phase 2 trial of RP-A501 in Danon disease. News release. Business Wire. September 15, 2026. Accessed October 8, 2026. https://www.businesswire.com/news/home/20260915485370/en/Rocket-Pharmaceuticals-Announces-FDA-Alignment-on-Path-to-Complete-Pivotal-Phase-2-Trial-of-RP-A501-in-Danon-Disease
3. Greenberg B, Taylor M, Adler E, et al. Phase 1 study of AAV9.LAMP2B gene therapy in Danon disease. N Engl J Med. 2025;392(10):972-983. doi:10.1056/NEJMoa2412392
4. Rocket Pharmaceuticals announces FDA has lifted the clinical hold on the pivotal phase 2 trial of RP-A501 for the treatment of Danon disease. Form 8-K, Exhibit 99.1. US Securities and Exchange Commission. August 20, 2025. Accessed October 8, 2026. https://www.sec.gov/Archives/edgar/data/1281895/000114036125032012/ef20054253_ex99-1.htm